Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic monitoring of bone turnover markers in osteoporosis treatment with denosumab
ChiCTR2500099711Phase 4Not yet recruiting
- Sponsor
- Xuzhou Cancer Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis (3 arms), sponsored by Xuzhou Cancer Hospital. Primary endpoint: New osteoporotic fracture rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2500099711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099711.